semaglutide cardiovascular outcomes news today 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Oral Semaglutide and Cardiovascular Outcomes

This remains a clinical judgment call without formal evidence backing

If you normally inject Tuesdays and want to switch to Thursdays, inject Tuesday as usual, then wait until Friday for your next dose (3 days instead of 7), then resume the 7-day schedule

Psychiatry 64 (3), 327337

By addressing excess weight and improving metabolic health, tirzepatide may help reduce one of the root causes of elevated blood pressure

In his many roles within the company, he has earned the right to be considered a Trusted Advisor within the market

The result is one injection that delivers both your weight loss medication and a vitamin that your body increasingly needs while taking it